Xeris Biopharma Holdings Past Performance
How has Xeris Biopharma Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XERS is currently unprofitable.
Growing Profit Margin: XERS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XERS is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare XERS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XERS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.4%).
Return on Equity
High ROE: XERS has a negative Return on Equity (-240.77%), as it is currently unprofitable.